title: Paeoniflorin suppresses lipid accumulation and alleviates insulin resistance by regulating the Rho kinase/IRS-1 pathway in palmitate-induced HepG2Cells.
abstract: In this study, we evaluated the effects of paeoniflorin (PF) on palmitate (PA)-induced insulin resistance and explored the potential molecular mechanisms in HepG2 cells. HepG2 cells were pre-treated with 3μM, 30μM, or 100μM PF for 1h followed by immediate stimulation with 0.25mM palmitate for 24h to induce hepatic steatosis. PF treatment could decrease PA-induced intracellular lipid deposition via inhibiting de novo lipid synthesis. PF treatment also restored insulin sensitivity by suppressing the activation of Rho kinase (ROCK) and the expression of serine phosphorylation of insulin receptor substrate (IRS)-1, thereby promoting Akt and glycogen synthase kinase (GSK)-3β phosphorylation. These results suggest that PF alleviates PA-induced hepatic steatosis and insulin resistance in HepG2 cells. Furthermore, the effect of PF may be associated with its role in inhibiting de novo lipid synthesis and in regulating the ROCK/IRS/Akt signalling pathways.
authors.affiliation: Yichun University, Key Laboratory for Research on Active Ingredients in Natural Medicine of Jiangxi Province, Yichun, 336000, China; Hebei University of Chinese Medicine, Department of Immunology and Pathobiology, Shijiazhuang, 050200, China.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Ma
authors.affiliation: Hebei General Hospital, Department of Infectious Diseases, Shijiazhuang, 050051, China.
authors.forename: Hongying
authors.initials: H
authors.lastname: Liu
authors.affiliation: The Second Hospital of Hebei Medical University, Department of Surgery, Shijiazhuang, 050000, China.
authors.forename: Weijie
authors.initials: W
authors.lastname: Wang
authors.affiliation: Hebei University of Chinese Medicine, Department of Pharmacology, Shijiazhuang, 050200, China.
authors.forename: Shengjiang
authors.initials: S
authors.lastname: Guan
authors.affiliation: Yichun University, Key Laboratory for Research on Active Ingredients in Natural Medicine of Jiangxi Province, Yichun, 336000, China. Electronic address: ycxyyjf@163.com.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Yi
authors.affiliation: Hebei University of Chinese Medicine, Department of Pharmaceutics, Shijiazhuang, 050200, China. Electronic address: chuli0614@126.com.
authors.forename: Li
authors.initials: L
authors.lastname: Chu
mesh_terms: D045744:Cell Line, Tumor; D005234:Fatty Liver / Q000188:drug therapy / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D005960:Glucosides / Q000494:pharmacology*; D000071679:Glycogen Synthase Kinase 3 beta / Q000378:metabolism; D056945:Hep G2 Cells; D006801:Humans; D007328:Insulin / Q000378:metabolism; D055504:Insulin Receptor Substrate Proteins / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids; D039821:Monoterpenes / Q000494:pharmacology*; D010168:Palmitates / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D054460:rho-Associated Kinases / Q000378:metabolism*; D006027:Glycosides
chemical_list: D005947:Glucose; D005960:Glucosides; D000071679:Glycogen Synthase Kinase 3 beta; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D008055:Lipids; D039821:Monoterpenes; D010168:Palmitates; D051057:Proto-Oncogene Proteins c-akt; D054460:rho-Associated Kinases; C526292:IRS1 protein, human; C015423:peoniflorin; D006027:Glycosides
keywords: Insulin resistance; Lipid accumulation; Paeoniflorin; Rho kinase